Alnylam Named a Top Biopharma Employer by Science Magazine
October 29 2020 - 3:06PM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, today announced that, for the second year in
a row, Science magazine has named the company a top employer in its
annual survey of the biotech and pharmaceutical industry.
“We are thrilled to be named a top employer by Science for the
second year in a row, as we continue to build a top-tier,
independent biopharmaceutical company founded on RNAi,” said John
Maraganore, Ph.D., Chief Executive Officer, Alnylam
Pharmaceuticals. “This continued recognition is a testament to the
efforts of our nearly 1,500 employees around the world who say
‘Challenge Accepted’ to advancing RNAi therapeutics as a new class
of innovative medicines to patients in need. It also embodies the
bold scientific endeavor and pioneering spirit that spurred our
founding over 18 years ago. We are pleased to see our collaborators
Regeneron reclaim the top ranking this year, as we share a
commitment to innovation and similarly bold science focused on
bringing new treatment options to patients.”
Results were based on 7,650 surveys of people in the industry
who rated companies on attributes such as corporate image,
leadership and direction, work culture/environment, and academic
and intellectual challenge. According to Science, the 2020 global
survey results were based on responses from North America (67
percent), Europe (19 percent) and the Asia/Pacific Rim (10
percent).
“Science has long recognized leaders in innovation within our
industry, and we are thrilled to be ranked on this esteemed list
for the second year in a row among our respected peers,” said
Akshay Vaishnaw, M.D., Ph.D., President, Research &
Development, Alnylam Pharmaceuticals. “It’s exciting to have our
science and culture continue to be recognized as we work hard to
discover and develop the next wave of RNAi therapeutics for
patients with serious diseases.”
For the complete feature and company rankings, please visit:
https://www.sciencemag.org/features/2020/10/top-employers-rapid-response-covid-19-diversity-and-innovation
About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a whole new
class of innovative medicines with the potential to transform the
lives of people afflicted with rare genetic, cardio-metabolic,
hepatic infectious, and central nervous system (CNS)/ocular
diseases. Based on Nobel Prize-winning science, RNAi therapeutics
represent a powerful, clinically validated approach for the
treatment of a wide range of severe and debilitating diseases.
Founded in 2002, Alnylam is delivering on a bold vision to turn
scientific possibility into reality, with a robust RNAi
therapeutics platform. Alnylam’s commercial RNAi therapeutic
products are ONPATTRO® (patisiran), approved in the U.S., EU,
Canada, Japan, Brazil, and Switzerland, and GIVLAARI® (givosiran),
approved in the U.S., Brazil and the EU. Alnylam has a deep
pipeline of investigational medicines, including six product
candidates that are in late-stage development. Alnylam is executing
on its "Alnylam 2020" strategy of building a multi-product,
commercial-stage biopharmaceutical company with a sustainable
pipeline of RNAi-based medicines to address the needs of patients
who have limited or inadequate treatment options. Alnylam is
headquartered in Cambridge, MA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201029006161/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Sep 2023 to Sep 2024